Citius Pharmaceuticals (CTXR)
Maxim Group analyst Michael Okunewitch maintained a Buy rating on Citius Pharmaceuticals yesterday and set a price target of $4.00. The company’s shares closed last Friday at $1.51, close to its 52-week low of $1.30.
According to TipRanks.com, Okunewitch is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Citius Pharmaceuticals with a $6.67 average price target.
Maxim Group analyst Jason McCarthy maintained a Hold rating on Cybin yesterday. The company’s shares closed last Friday at $1.06, close to its 52-week low of $0.82.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Cybin is a Moderate Buy with an average price target of $8.24.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CTXR: